drugset / Trial / NCT00165399

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

NCT00165399

Phase 2 Completed 62 enrolled Dana-Farber Cancer Institute
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug

Timeline

Start
2004-03
Primary completion
2005-12-31
Completion
2005-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified Oral
Subject Docetaxel Small molecule Intravenous
Subject Goserelin Other / unclassified Other
Subject estramustine Other / unclassified Oral